![]() |
![]() |
Anim Biosci > Volume 36(3); 2023 > Article |
|
CONFLICT OF INTEREST
We certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.
AUTHOR CONTRIBUTIONS
Conceptualization, AYQ, MIN, and JC; validation, AYQ, SR, and JC; formal analysis, PKR, and BMT; resources, AYQ, IMS, JC; writing—original draft preparation, AYQ, MIN, and SR; writing—review and editing, AYQ, IMS, and MIN; visualization, XF, PKR, SB, and BMT; supervision, JC; project administration, JC; funding acquisition, JC. All authors have read and agreed to the published version of the manuscript.
Antioxidant | Study type | Specie | Dose used | Outcome | Reference |
---|---|---|---|---|---|
SOD | In-vitro | Stallion | 25, 50 U/mL | Improved progressive motility and viability of sperm | [48] |
CAT | In-vitro | Human | 200 U/mL |
Higher progressive motile sperm Reduced DNA-damaged sperm |
[55] |
Camel | 500 IU/mL | Higher total and progressive motile sperm | [56] | ||
GPx, SOD | In-vitro | Bull |
0.0, 0.5, 1.0 mM 0, 250, 500 U/mL |
Non-return rates are 74% and 73.9% Improved sperm motility (6% to 11%) |
[154] |
SOD, CAT, GPx | In-vitro | Dog | 15 IU/mL |
Higher progressive motile sperm Significantly higher DNA integrity |
[49] |
Ascorbate & CAT | In-vitro | Human |
300, 600 μM 200, 400 U/mL |
Reduced significantly ROS levels in post-thaw sperm | [54] |
SOD, CAT | In-vitro | Human | 200 U/mL |
Significantly improved sperm quality Reduced LPO |
[57] |
Antioxidant | Study type | Specie | Dose used | Outcome | Reference |
---|---|---|---|---|---|
GSH | In-vitro | Donkey | 0, 2, 4, 6, 8, 10 mM |
Significantly higher motility & kinematic parameters Higher sperm viability |
[59] |
In-vivo | Human | 600 mg | Significantly improved fertility | [60] | |
Reduced GSH & SOD | In-vitro | Bull |
GSH: 5, 7.5 mM SOD: 50, 100 U/mL |
Improved total and progressive motility parameters | [61] |
Cysteine | In-vivo | Human | 600 mg |
Significantly improved sperm count and motility Significantly decreased abnormal morphology DNA fragmentation and protamine deficiency |
[63] |
In-vitro | Human | 1.0 mg/mL |
Significantly improved sperm function and motility Significantly decreased ROS production |
[64] | |
Buffalo | 0.0, 0.5, 1.0, 2.0, 3.0 mM | Improved antioxidant status, freeze-thaw quality, and in-vivo fertility | [65] | ||
Cysteine & SOD | In-vitro | Chicken |
5 mM 200 U/mL |
Prevented the reduction in motility, viability, and mitochondrial membrane potential Protected sperm against apoptotic changes |
[66] |
Cysteine & Erythioneine | In-vitro | Ram | 0, 1, 2, 4 mM | Improved freeze-thaw sperm motility and mitochondrial activity | [67] |
Vitamin C | In-vivo | Human | 5, 10, 20, 60, 250 mg/d | Reduced oxidative DNA damage of sperm | [68] |
50, 100, 200, 400, 800, 1,000, 2,000, 4,000 μg | Improved sperm motility and viability through reduced ROS production | [73] | |||
0, 200, 1,000 mg/d | Improved sperm quality | [69] | |||
1,000 mg/d | Significant rise in sperm count, sperm motility, and sperm with normal morphology | [70] | |||
500 mg/d | Improved sperm motility and morphology | [71] | |||
Rat | 25 mg/kg/d |
Protective role on cyclophosphamide-induced testicular dysfunction Alleviates the cyclophosphamide-induced OS |
[72] | ||
0.88 mg/kg | Higher sperm motility, viability, and count | [155] | |||
Vitamin E | In-vivo | Chicken | 0, 20, 40, 80, 160 mg/kg |
Higher sperm viability and motility (40–160 mg/kg) Higher sperm concentration (80 mg/kg) |
[44] |
200 mg/kg diet |
Increased both sperm count and motility Reduced percentage of dead sperm |
[78] | |||
Human | 600 mg/d | Significant improvement in in-vitro sperm function | [75] | ||
100 mg/d |
Significantly higher sperm motility Significantly decreased MDA levels |
[77] | |||
Vitamins C & E | In-vivo | Human |
1,000 mg/d 800 mg/d |
Increased ejaculate volume, sperm count, and motility | [81] |
1,000 mg/d | Markedly reduced DNA-fragmented sperm | [82] | |||
In-vitro | Human | 10 mM | Minimum improvement in sperm motility | [31] | |
Vitamins C & E, CAT, Hypotaurine, Cysteine, GSH | In-vitro | Human |
0.2 and 1 mM 2,600 U/mL 1 & 10 mM 1 & 10 mM 1 & 10 mM |
Protects against OS | [83] |
Vitamins C & E, GSH | In-vitro | Human | 200 mg, 200 mg, 400 mg | Reduced OS | [84] |
Vitamins C & E, Urate, Cysteine | In-vitro | Human |
300, 600 μM 30, 60 μM 200, 400 μM 5, 10 μM |
Improved sperm DNA integrity | [74] |
Mesterolone & Vitamin C | In-vivo | Human |
50 mg 200 mg |
No improvement in male fertility | [86] |
Cysteine, Vitamin A, & Vitamin E | In-vivo | Human |
600 mg/d 30 and 180 mg/d |
Neutralized the ROS and improve sperm count No effect on sperm motility |
[85] |
Selenium | In-vivo | Human | 100 μg/d | Significant rise in plasma selenium concentration and sperm motility | [156] |
400 U/d 200 μg/d |
Significantly higher sperm motility, viability, and fertility | [87] | |||
400 mg/d 225 μg/d |
Significantly improved sperm motility Significantly decreased MDA levels |
[76] | |||
Rebamipide | In-vitro | Human | 10, 30, 100, 300 μM |
Decreased ROS level and LPO No effect on sperm viability |
[80] |
Taurine | In-vitro | Sheep | 0, 10, 20, 40, 80, 100 mM | Reduced LPO and improved semen parameters | [93] |
Cat | 50 mM | Higher sperm motility, Reduced abnormal sperms with sperm defects | [94] | ||
Stallion | 70, 100 mM | Improved sperm survival | [95] | ||
Donkey | 0, 20, 40, 60 mM | Significantly improved sperm motility | [96] | ||
Hamster | 0, 2×10−3, 2×10−4, 2×10−5 M | Improved motility and promote capacitation | [90] | ||
Hypotaurine | In-vitro | Hamster | 10 mM | Restore sperm motility and viability | [92] |
Taurine & Hypotaurine | In-vitro | Rabbit | 0.5 mM | Reduced LPO and restored motility | [91] |
Taurine & Trehalose | In-vitro | Cattle Bull |
50 mM 100 mM |
Significantly improved freeze-thaw motility, viability, and plasma membrane integrity | [97] |
Buffalo Bull |
50 mM 100 mM |
Improved motility, viability, and membrane integrity Low numbers of capacitated sperm |
[88] | ||
Taurine, QR, & GSH | In-vitro | Ram | 40 mM, 5 μg/mL, 5 mM |
Reduced LPO Improved freeze-thaw semen quality |
[98] |
CoQ10 | In-vivo | Human | 200 mg/d |
Improved sperm concentration, progressive motility, total motility, and semen antioxidant status Reduced ROS level and SDF percentage |
[100] |
Stallion | 1 gm/d | Improved semen quality | [110] | ||
In-vivo & In-vitro | Human |
5, 50 μM 60 mg |
Improved sperm motility and fertilization rate | [157] | |
Buffalo bull | 30 Mm | Improved sperm parameters and fertility | [105] | ||
Rooster | 0, 1, 2, 5, 10 μM |
Significantly higher total sperm, progressive motilities, membrane functionality, viability, and mitochondria active potential Reduced LPO |
[104] | ||
Buck | 0, 0.5, 1, 1.5 μM | Improved sperm motility, viability, and plasma membrane functionality | [106] | ||
Giant grouper | 0, 25, 50, 100 μM | Improved total sperm motility, fertilization rate, and reduced DNA fragmentation | [103] | ||
Boar | - | Increase the sperm characteristics and prolong the survival of liquid storage of sperm | [108] | ||
Stallion | 40 & 80 μg/mL | No notable effect of semen quality | [109] | ||
CoQ10 & L-carnitine | In-vivo | Rat |
10 mg/kg/d 350 mg/kg/d |
Significantly improved sperm quality and hormonal profile by weakening the high and oxidized LDL | [102] |
CoQ10 & Ellagic acid | In-vitro | Ram |
0.5 μM 0.25 mM |
Higher total sperm, progressive motility, and viability No effect of sperm antioxidant level |
[107] |
Antioxidant | Route | Specie | Dose used | Outcome | Reference |
---|---|---|---|---|---|
AXN | In-vivo | Human | 0, 16 mg/kg | Positive effect on sperm parameters and fertility | [113] |
0.5, 1, 2 μM | Inhibited LPO | [158] | |||
Ram | 0, 0.5, 1, 2, 4 μM |
Improved sperm vitality and membrane integrity Significantly reduced ROS production |
[116] | ||
Rat | 720 mg/kg | Improved sperm viability, normal morphology, and DNA integrity | [115] | ||
In-vitro | Boar | 0, 0.5, 1, 2, 5 μM | Improved freeze-thaw semen quality, inhibited LPO | [117] | |
Dog | 0, 0.5, 1, 2 μM | Improved freeze-thaw sperm quality | [118] | ||
Ram | 0, 0.5, 1, 2, 4 μM |
Decreased acrosome abnormalities Improve semen quality and fertility rate |
[119] | ||
β-carotene & AXN | In-vivo | Goldfish | 50, 100, 150 mg/kg | Improved osmolality, motility, fertilization rate, and sperm concentration | [112] |
AXN & Vitamins E and C | In-vivo | Rat |
100 mg/kg 100, and 200 mg/kg |
Improved fertility | [114] |
Kinetin | In-vivo | Wheat Seedling | 1 μM | Improved growth, antioxidant, and chlorophyll content | [120] |
Rat | 0.25, 0.5, 1 mg/kg |
Reduced organ damage and OS Inhibited the apoptosis |
[122] | ||
In-vitro | Dog | 0, 25, 50, 100, 200 μM | Reduced OS and improved the freeze-thaw semen quality | [123] | |
Ram | 0, 25, 50, 100, 200 μM | Enhanced sperm kinematics, viability, plasma membrane functionality, and reduced LPO | [124] | ||
MYO | In-vivo & In-vitro | Human | 15 μL/mL | Improved sperm quality and motility | [126] |
2 g |
Increased acrosome-reacted sperm, sperm concentration, and progressive motility Optimized serum LH, FSH, and inhibin |
[127] | |||
No effect on mitochondrial function of sperm Increase sperm number with high MMP |
[128] | ||||
Increase sperm motility and sperm number retrieved after swim-up | [129] | ||||
Improved total motility, progressive motility, and reduced DNA fragmentation Ineffective in inhibiting ROS level |
[133] | ||||
20 mg/mL |
Improvement of sperm vitality and motility Reduction of ROS-induced sperm defects |
[134] | |||
Dog | 1, 2 mg/mL | Protected against OS and improved freeze-thaw sperm quality | [130] | ||
Catfish | 5, 10, 20, 40 mg | Increased sperm motility, viability, and DNA integrity | [131] | ||
MYO & Melatonin | In-vitro | Goat | - | Reduced ROS production, DNA damage, and LPO | [132] |
In-vitro | Rabbit | 0, 25, 50, 100, 200 μM | Reduced H202 and LPO | [135] | |
50 μM | Higher sperm motility, viability, and DNA integrity | [139] | |||
Goat | 10, 20 μM | Improves freeze-thaw sperm motion characteristics and inhibited LPO | [136] | ||
Bull | 25, 50, 100, 200 μg/mL | No beneficial effect of motility, plasma membrane integrity, and sperm defects | [137] | ||
Dog | 0, 25, 50, 100 μM | Reduced oxidative damage and improved the semen quality | [138] | ||
0.15 mM | Improved sperm motility and zona binding ability, reduced DNA fragmentation | [140] | |||
Selenium | In vitro | Human | 2 μg/mL | Enhanced motility, viability, and MMP | [143] |
Zn2+ | In-vitro | Human | 12.5 nM | Improved sperm parameters, and reduced DNA damage | [145] |
50 μM | Enhanced sperm total and progressive motility | [149] | |||
Zn2+, D-aspartate, CoQ10 | In-vitro | Human |
1, 10, 100 μg/mL 5, 50, 500, 5,000 μg/mL 4, 40, 400 μg/mL |
Improved progressive sperm motility, reduced DNA fragmentation | [148] |
Sericin | In-vitro | Buck | 0%, 0.25%, 0.5% | Ameliorated the freeze-thaw semen quality by improving the antioxidative status and minimizing the leakage of intracellular enzymes (0.25% Sericin) | [150] |
Bull | 0%, 0.25%, 0.5%, 1.5%, 2% | Improved freeze-thaw semen quality by protecting against OS | [151] | ||
Rabbit | 0%, 0.1%, 0.5% |
Enhanced osmotic tolerance and freeze-thaw sperm quality, Reduces the ability of rabbit sperm cells to undergo in-vitro-induced acrosome reaction, |
[152] | ||
Stallion | 0.25% | Improved sperm DNA integrity and its resistance to ROS and LPO | [153] |
![]() |
![]() |